SequelSEC

PTC THERAPEUTICS, INC. PTCT

Pharmaceutical Preparations · CIK 0001070081 · Fiscal year ends 1231

Revenue
$1.73B
Fiscal year ended 2025-12-31
Operating income
$866.94M
Fiscal year ended 2025-12-31
Free cash flow
$702.34M
Fiscal year ended 2025-12-31

PTC THERAPEUTICS, INC. (PTCT) reported revenue of $1.73B and net income of $682.64M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from PTC THERAPEUTICS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

PTC THERAPEUTICS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$1.73B$806.78M$937.82M$698.80M$538.59M$380.77M$306.98M$264.73M$194.39M$82.70M
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$12.14M$12.67M$4.58M$0
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$189.82MUnavailable
Operating income$866.94M-$302.57M-$439.50M-$447.41M-$374.44M-$431.77M-$241.16M-$115.68M-$64.29M-$132.06M
Net income$682.64M-$363.30M-$626.60M-$559.02M-$523.90M-$438.16M-$251.58M-$128.08M-$79.00M-$142.11M
Research & development$455.25M$534.48M$666.56M$651.50M$540.68M$477.64M$257.45M$171.98M$117.46M$117.63M
Weighted-average diluted sharesshares 88.31Mshares 76.85Mshares 74.84Mshares 71.73Mshares 70.47Mshares 66.03Mshares 58.86MUnavailableUnavailableUnavailable
Pretax income$696.62M-$363.12M-$696.11M-$587.49M-$518.34M-$402.93M-$239.93M-$128.11M-$77.66M-$141.54M
Income tax expense$13.98M$176.00K-$69.51M-$28.47M$5.56M$35.23M$11.65M-$29.00K$1.34M$569.00K
Diluted EPS$7.78$-4.73$-8.37$-7.79$-7.43$-6.64$-4.27UnavailableUnavailableUnavailable
Selling, general & administrative$347.14M$300.91M$332.54M$326.00M$285.77M$245.16M$202.54M$153.55M$121.27M$97.13M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$121.27M$97.13M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

PTC THERAPEUTICS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Cash & equivalents$984.65M$779.71M$594.00M$279.83M$189.72M$208.81M$288.03M$169.50M$111.79M$58.32M
Total assets$2.90B$1.71B$1.90B$1.71B$1.94B$2.21B$1.62B$1.12B$391.65M$269.34M
Current assets$2.27B$1.37B$1.22B$693.78M$954.37M$1.23B$779.28M$320.86M$249.06M$261.29M
Total liabilities$3.10B$2.80B$2.71B$2.05B$1.94B$1.73B$1.03B$768.50M$235.22M$149.76M
Current liabilities$968.43M$580.98M$603.10M$406.24M$509.35M$277.33M$235.86M$166.80M$82.05M$49.62M
Total equity incl. NCI-$205.31M-$1.10B-$818.56M-$347.09M$1.44M$481.98M$594.33M$350.73M$156.44M$119.58M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$79.65M$23.19M$30.58M$21.81M$15.86M$18.70M$19.28M$16.12M$10.75M$0
Accounts receivable$181.62M$158.55M$160.82M$155.61M$110.46M$69.93M$55.54M$67.91M$40.39M$24.93M
Goodwill$82.34M$82.34M$82.34M$82.34M$82.34M$82.34M$82.34M$82.34M$0Unavailable
Long-term debtUnavailable$285.41M$284.21M$571.72M$281.89M$309.14M$293.86M$141.35M$144.97M$98.22M
Accounts payable$45.49M$17.27M$6.04M$27.27M$23.03M$18.66M$10.32M$6.00M$15.28M$6.30M

Cash flow

PTC THERAPEUTICS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Operating cash flow$711.20M-$107.69M-$158.42M-$356.65M-$251.33M-$194.07M-$98.64M-$27.64M-$10.06M-$103.57M
Capital expenditures$8.86M$6.50M$28.44M$32.02M$28.21M$17.84M$13.76M$7.10M$3.10M$1.78M
Investing cash flow-$861.98M$44.18M-$176.74M$290.18M$219.18M-$561.55M-$387.24M-$42.61M$13.12M$104.48M
Financing cash flow$331.09M$255.87M$646.40M$167.95M$20.88M$668.72M$613.21M$131.57M$44.22M$968.00K
Net change in cash$203.02M$185.03M$314.36M$98.71M-$19.09M-$79.22M$126.03M$57.71M$53.47M$299.00K
Stock-based compensation$74.55M$74.62M$101.64M$110.33M$103.51M$70.32M$42.13M$33.25M$30.56M$35.01M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$38.82M$75.66M$236.59M$128.84M$64.13M$43.49M$32.18M$26.09M$17.68M$3.29M

Derived

PTC THERAPEUTICS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Free cash flow$702.34M-$114.19M-$186.86M-$388.67M-$279.54M-$211.91M-$112.40M-$34.74M-$13.16M-$105.34M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable97.6%Unavailable
Operating margin50.1%-37.5%-46.9%-64.0%-69.5%-113.4%-78.6%-43.7%-33.1%-159.7%
FCF margin40.6%-14.2%-19.9%-55.6%-51.9%-55.7%-36.6%-13.1%-6.8%-127.4%
SBC / revenue4.3%9.2%10.8%15.8%19.2%18.5%13.7%12.6%15.7%42.3%
Current ratio2.35x2.35x2.02x1.71x1.87x4.44x3.30x1.92x3.04x5.27x
Revenue YoY growth114.5%-14.0%34.2%29.7%41.4%24.0%16.0%36.2%135.0%Unavailable
Net margin39.4%-45.0%-66.8%-80.0%-97.3%-115.1%-82.0%-48.4%-40.6%-171.8%
R&D / revenue26.3%66.2%71.1%93.2%100.4%125.4%83.9%65.0%60.4%142.2%
CapEx / revenue0.5%0.8%3.0%4.6%5.2%4.7%4.5%2.7%1.6%2.1%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rate2.0%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PTCT in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-30View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-19View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-06View SEC filing

Companies in the same industry

Reconciliation checks needing review

3 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2019-12-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2018-12-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2016-12-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.